华特达因(000915)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

000915 华特达因

已收盘 02-06 15:00:00

{"stockData":{"symbol":"000915","market":"SZ","secType":"STK","nameCN":"华特达因","latestPrice":32.13,"timestamp":1770361428000,"preClose":32.07,"halted":0,"volume":4959900,"delay":0,"changeRate":0.0019,"floatShares":234000000,"shares":234000000,"eps":2.3823,"marketStatus":"已收盘","change":0.06,"latestTime":"02-06 15:00:00","open":32.06,"high":32.71,"low":32.06,"amount":161000000,"amplitude":0.0203,"askPrice":32.14,"askSize":2,"bidPrice":32.13,"bidSize":48,"shortable":0,"etf":0,"ttmEps":2.3823,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770600600000},"marketStatusCode":5,"adr":0,"adjPreClose":32.07,"symbolType":"stock","openAndCloseTimeList":[[1770341400000,1770348600000],[1770354000000,1770361200000]],"highLimit":35.28,"lowLimit":28.86,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":234331485,"isCdr":false,"pbRate":2.64,"roa":"--","peRate":13.486966,"roe":"13.79%","epsLYR":2.2,"committee":0.651116,"marketValue":7529000000,"turnoverRate":0.0212,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-02-09。","floatMarketCap":7524000000},"requestUrl":"/m/hq/s/000915","defaultTab":"news","newsList":[{"id":"2608181825","title":"华特达因：儿童褪黑素颗粒产品曼乐静已在京东和阿里开始线上销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2608181825","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608181825?lang=zh_cn&edition=full","pubTime":"2026-02-03 16:14","pubTimestamp":1770106440,"startTime":"0","endTime":"0","summary":"华特达因(000915.SZ)2月3日在投资者互动平台透露，其儿童褪黑素颗粒产品曼乐静已正式在京东、阿里等线上平台开启销售，并计划后续逐步拓展至国内各地线下医院，实现线上线下全渠道覆盖。公司当前生产经营及销售状况均保持正常状态，针对股价波动问题，公司表示这主要受宏观环境等多重因素影响。未来，华特达因将继续聚焦主业，不断提升自身核心竞争力，致力于以出色的经营业绩回馈广大投资者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260203162650a6cdae21&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260203162650a6cdae21&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B29SXG58.USD","89618","LU0211977185.USD","LU0572944931.SGD","LU1813983027.USD","LU0384037296.USD","LU0417516738.SGD","LU1794554557.SGD","LU2039709279.SGD","LU1642822792.SGD","LU1328277881.USD","LU0348805143.USD","LU0327786744.USD","LU0588545490.SGD","LU0588546209.SGD","LU0594300419.USD","LU1770036033.HKD","LU0228367735.SGD","BK1575","LU1282651121.HKD","LU1808992512.USD","LU0359201612.USD","LU0259732245.USD","BK1249","IE00BGV7N243.SGD","LU0588545730.USD","LU0871576103.HKD","LU0314109678.HKD","LU0469268626.HKD","LU0164880469.USD","09988","LU0431992006.USD","LU1044876610.USD","LU0499858438.USD","LU1282649810.SGD","LU1366334651.USD","LU0348825331.USD","LU0456827905.SGD","LU1366334578.USD","SG9999001226.SGD","BK1615","LU0320764599.SGD","LU1044875133.USD","LU0370786039.SGD","LU0163747925.USD","BABAF","LU0499858602.USD","LU0051755006.USD","LU0828237510.HKD","LU1719994722.HKD","BABA","89988","BK1619","000915","LU1023057109.AUD","LU0488056044.USD","LU0588545904.SGD","09618","LU0348735423.USD","IE00B3M56506.USD","BK1142","LU0865486749.SGD","LU0650527681.SGD","LU1044874839.SGD","LU0531971595.HKD","LU0149721374.USD","BK1588","LU0039217434.USD","LU0164865239.USD","LU0672654166.SGD","LU0345775950.USD","LU1251922891.USD","LU1481107354.HKD","IE0032431581.USD","LU0048580855.USD","LU0084288322.USD","LU0128522157.USD","LU0359202008.SGD","LU0029875118.USD","LU1770034418.SGD","LU0868486357.SGD","LU0052750758.USD","LU0140636845.USD","LU0543330483.HKD","LU0320764755.SGD","LU0315179316.USD","LU1303224171.USD","LU0231483743.USD","SG9999002828.SGD","BK1502","LU0345776255.USD","LU0359201885.HKD","LU2242644610.SGD","LU1282649067.USD","LU0456846285.SGD","LU0456842615.SGD","LU0708995583.HKD","SG9999002562.SGD","LU2257852520.SGD","LU0417516902.SGD","BK1591","LU0791590937.USD","LU0315178854.USD","LU1720050803.USD","LU0228659784.USD","LU0307460666.USD","LU1282651048.USD","BK1610","LU0791591158.USD","LU0293314216.USD","LU1224444064.USD"],"gpt_icon":0},{"id":"2608823959","title":"华特达因：公司暂无出海业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2608823959","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608823959?lang=zh_cn&edition=full","pubTime":"2026-02-03 16:06","pubTimestamp":1770105974,"startTime":"0","endTime":"0","summary":"证券之星消息，华特达因(000915)02月03日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好！年报中并未披露贵公司的分地区销售情况，请问贵公司有无产品直接出口到境外？华特达因回复：您好！公司暂无出海业务。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020300024882.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","000915","BK0175","BK0239","BK0186","BK0122"],"gpt_icon":0},{"id":"2608823692","title":"华特达因：丙戊酸钠口服溶液和盐酸可乐定缓释片获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2608823692","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608823692?lang=zh_cn&edition=full","pubTime":"2026-02-03 16:03","pubTimestamp":1770105803,"startTime":"0","endTime":"0","summary":"证券之星消息，华特达因02月03日在投资者关系平台上答复投资者关心的问题。公司的在研发和，准备研发成功的儿童药还有哪些？","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020300024500.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0186","BK0239","BK0188","BK0175","000915","BK0122"],"gpt_icon":0},{"id":"2607803638","title":"华特达因（000915）披露原全资子公司破产清算事项进展公告，1月29日股价上涨0.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607803638","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607803638?lang=zh_cn&edition=full","pubTime":"2026-01-29 22:48","pubTimestamp":1769698097,"startTime":"0","endTime":"0","summary":"截至2026年1月29日收盘，华特达因报收于31.85元，较前一交易日上涨0.35%，最新总市值为74.63亿元。该股当日开盘31.56元，最高31.86元，最低31.44元，成交额达9524.82万元，换手率为1.28%。近日，华特达因发布《关于原全资子公司破产清算事项的进展公告》。该公司原为山东华特达因健康股份有限公司全资子公司，曾于2023年10月申请破产清算，法院已于2024年12月11日裁定宣告其破产，并于2025年8月13日裁定终结破产程序。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012900043930.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000915","BK0186","BK0175","BK0188","BK0122","BK0239"],"gpt_icon":0},{"id":"2605145941","title":"股市必读：华特达因（000915）1月20日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2605145941","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605145941?lang=zh_cn&edition=full","pubTime":"2026-01-21 03:10","pubTimestamp":1768936217,"startTime":"0","endTime":"0","summary":"截至2026年1月20日收盘，华特达因报收于32.44元，下跌0.22%，换手率0.99%，成交量2.33万手，成交额7569.02万元。依据中国证监会和深交所的相关规定，上市公司应当在每个会计年度结束之日起四个月内披露年度报告。公司严格按照中国证监会和深交所的相关要求组织年度报告编制和披露工作，2025年度预计经营业绩不属于应当披露业绩预告的范围，年度报告预约披露时间为2026年4月24日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012100001333.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000915","BK0122","BK0239","BK0175","BK0186","BK0188"],"gpt_icon":0},{"id":"2604966162","title":"华特达因：2025年度业绩不属应披露预告范围","url":"https://stock-news.laohu8.com/highlight/detail?id=2604966162","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604966162?lang=zh_cn&edition=full","pubTime":"2026-01-20 15:04","pubTimestamp":1768892658,"startTime":"0","endTime":"0","summary":"证券之星消息，华特达因(000915)01月20日在投资者关系平台上答复投资者关心的问题。投资者提问：公司25年年报披露时间较往年晚了一个多月，原因是是什么，以及是否会发布业绩预告华特达因回复：您好！依据中国证监会和深交所的相关规定，上市公司应当在每个会计年度结束之日起四个月内披露年度报告。公司严格按照中国证监会和深交所的相关要求组织年度报告编制和披露工作，2025年度预计经营业绩不属于应当披露业绩预告的范围，年度报告预约披露时间为2026年4月24日。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012000018001.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0188","BK0186","000915","BK0239","BK0122"],"gpt_icon":0},{"id":"2604416218","title":"华特达因：公司目前与雀巢公司没有业务往来","url":"https://stock-news.laohu8.com/highlight/detail?id=2604416218","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604416218?lang=zh_cn&edition=full","pubTime":"2026-01-20 15:04","pubTimestamp":1768892658,"startTime":"0","endTime":"0","summary":"证券之星消息，华特达因(000915)01月20日在投资者关系平台上答复投资者关心的问题。投资者提问：贵公司和雀巢是否有业务来往？华特达因回复：您好！公司目前与雀巢公司没有业务往来。谢谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012000018006.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0175","BK0186","BK0122","000915","BK0188"],"gpt_icon":0},{"id":"2604162978","title":"华特达因：构建儿童用药与大健康产品矩阵","url":"https://stock-news.laohu8.com/highlight/detail?id=2604162978","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604162978?lang=zh_cn&edition=full","pubTime":"2026-01-20 15:04","pubTimestamp":1768892658,"startTime":"0","endTime":"0","summary":"证券之星消息，华特达因01月20日在投资者关系平台上答复投资者关心的问题。利用伊可新的品牌力，主打从小到老的全生命周期维生素产品。多年来，公司秉持“使千千万万中国儿童健康强壮”的使命，致力于“成为儿童保健和治疗领域的领军企业”。围绕这一使命愿景，公司持续专注专研、深耕细作，构建形成了从研发到生产、从产品到营销等各方面的核心能力和儿童营养健康领域领军品牌的地位。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012000018005.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0122","BK0239","000915","BK0175","BK0186"],"gpt_icon":0},{"id":"2601801869","title":"华特达因（000915）披露子公司达因药业获得药品注册证书，1月7日股价下跌1.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601801869","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601801869?lang=zh_cn&edition=full","pubTime":"2026-01-07 22:28","pubTimestamp":1767796099,"startTime":"0","endTime":"0","summary":"截至2026年1月7日收盘，华特达因报收于33.47元，较前一交易日下跌1.01%，最新总市值为78.43亿元。该股当日开盘33.81元，最高33.88元，最低33.41元，成交额达1.04亿元，换手率为1.32%。公司近日发布公告称，其子公司山东达因海洋生物制药股份有限公司收到国家药品监督管理局颁发的盐酸可乐定缓释片《药品注册证书》。同时提示，药品未来的销售情况将受到医药行业政策、招标采购及市场环境等因素影响，存在不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010700039010.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000915","BK0186","BK0122","BK0188","BK0175","BK0239"],"gpt_icon":0},{"id":"2601201858","title":"华特达因(000915.SZ)子公司取得一项药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2601201858","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601201858?lang=zh_cn&edition=full","pubTime":"2026-01-07 15:54","pubTimestamp":1767772447,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华特达因(000915.SZ)公告，公司的子公司山东达因海洋生物制药股份有限公司(简称达因药业)收到国家药品监督管理局颁发的《药品注册证书》，药品名称为：盐酸可乐定缓释片。本品用于单独或辅助中枢兴奋药治疗6-17岁儿童和青少年的注意缺陷多动障碍(ADHD)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1389787.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000915","BK0122","BK0239","BK0175","BK0186","BK0188"],"gpt_icon":0},{"id":"2592026961","title":"华特达因：Mumheart液体钙镁锌饮亮相进博会","url":"https://stock-news.laohu8.com/highlight/detail?id=2592026961","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592026961?lang=zh_cn&edition=full","pubTime":"2025-12-17 15:06","pubTimestamp":1765955186,"startTime":"0","endTime":"0","summary":"证券之星消息，华特达因12月17日在投资者关系平台上答复投资者关心的问题。Mumheart品牌跨境产品当前销售额、复购率如何？“Mumheart”液体钙镁锌饮采用品牌专研的“DYNE-KidHealthT+量身定制超效吸收”技术，一袋补充钙、镁、锌等7种关键营养。目前，该品牌已在第八届进博会上亮相，公司正在为产品上市做相关筹备工作。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121700018287.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0122","000915","BK0186","BK0188","BK0239","BK0175"],"gpt_icon":0},{"id":"2588854880","title":"华特达因：小儿布洛芬栓和伊可新AD剂市场需求稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=2588854880","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588854880?lang=zh_cn&edition=full","pubTime":"2025-12-02 11:37","pubTimestamp":1764646651,"startTime":"0","endTime":"0","summary":"证券之星消息，华特达因(000915)12月02日在投资者关系平台上答复投资者关心的问题。投资者提问：流感季到来，公司的抗流感药物，和伊可新AD剂，销量有没有增加？华特达因回复：您好！公司会根据市场需求灵活调整生产及销售，目前公司的小儿布洛芬栓和伊可新AD剂等市场需求稳定。公司会持续关注市场动态，公司现有生产完全能够满足市场对各类产品的需求。感谢您的关注!以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200013043.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0186","BK0188","BK0122","BK0239","000915","BK0175"],"gpt_icon":0},{"id":"2588085501","title":"华特达因：褪黑素颗粒预计2026年初上市销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2588085501","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588085501?lang=zh_cn&edition=full","pubTime":"2025-12-02 11:34","pubTimestamp":1764646443,"startTime":"0","endTime":"0","summary":"证券之星消息，华特达因(000915)12月02日在投资者关系平台上答复投资者关心的问题。投资者提问：请问，褪黑素产品预计年底前能否上市？近期股价下跌是否跟褪黑素产品未能上市有关？华特达因回复：您好！公司代理的褪黑素颗粒产品预计将于2026年初正式实现上市销售，目前正积极的推进曼乐静产品上市的相关准备工作。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200012788.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0122","BK0188","000915","BK0186","BK0175"],"gpt_icon":0},{"id":"2584769829","title":"股市必读：华特达因（000915）11月14日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2584769829","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584769829?lang=zh_cn&edition=full","pubTime":"2025-11-17 02:27","pubTimestamp":1763317633,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，华特达因报收于35.6元，上涨0.56%，换手率2.34%，成交量5.48万手，成交额1.96亿元。按照持股比例计算，归属于上市公司股东的净利润为4.08亿元。公司代理的褪黑素产品目前尚未实现上市销售，目前正积极的推进曼乐静产品上市的相关准备工作。投资者： 尊敬的董秘，您好，贵司25年3季度扣非利润不到7千万，环比一、二季度均下降50%左右。今年三季度利润却再度大幅下滑，营收也下降1至2亿，想请问董秘是什么原因造成的。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111700000871.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0188","BK0239","000915","BK0122","BK0186"],"gpt_icon":0},{"id":"2583527550","title":"华特达因：代理的褪黑素产品尚未实现上市销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2583527550","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583527550?lang=zh_cn&edition=full","pubTime":"2025-11-14 15:06","pubTimestamp":1763103978,"startTime":"0","endTime":"0","summary":"证券之星消息，华特达因(000915)11月14日在投资者关系平台上答复投资者关心的问题。投资者提问：公司代理的褪黑素产品上市没有销售的怎么样？华特达因回复：您好！公司代理的褪黑素产品目前尚未实现上市销售，目前正积极的推进曼乐静产品上市的相关准备工作。谢谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400018898.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0122","000915","BK0175","BK0188","BK0239","BK0186"],"gpt_icon":0},{"id":"2583528672","title":"华特达因：医药业务净利润7.57亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2583528672","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583528672?lang=zh_cn&edition=full","pubTime":"2025-11-14 11:37","pubTimestamp":1763091437,"startTime":"0","endTime":"0","summary":"证券之星消息，华特达因(000915)11月14日在投资者关系平台上答复投资者关心的问题。投资者提问：您好贵公司三季度报告中，表述医药业务净利润7.57亿，但是实际是4.08亿，请问其中少去的2.5亿是哪个行业亏损造成的？谢谢华特达因回复：您好！公司医药业务主要由控股子公司达因药业及达因康健、达因高科运营。2025年前三季度，该板块实现净利润7.57亿元。按照持股比例计算，归属于上市公司股东的净利润为4.08亿元。谢谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400014953.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000915","159938","09939"],"gpt_icon":0},{"id":"2583528660","title":"华特达因：前三季度扣非后归母净利润同比增长超15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583528660","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583528660?lang=zh_cn&edition=full","pubTime":"2025-11-14 11:37","pubTimestamp":1763091436,"startTime":"0","endTime":"0","summary":"投资者提问：尊敬的董秘，您好，贵司25年3季度扣非利润不到7千万，环比一、二季度均下降50%左右。今年三季度利润却再度大幅下滑，营收也下降1至2亿，想请问董秘是什么原因造成的。在行业内企业总体面临巨大的经营压力的情况下，公司聚焦并加强主业经营管理，加大市场营销力度，提高产品销售收入，努力实现了前三季度扣非后归母净利润超15%的同比增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400014951.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000915"],"gpt_icon":0},{"id":"2583528981","title":"华特达因：拓展“中大童”市场应对出生率下降","url":"https://stock-news.laohu8.com/highlight/detail?id=2583528981","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583528981?lang=zh_cn&edition=full","pubTime":"2025-11-14 11:37","pubTimestamp":1763091435,"startTime":"0","endTime":"0","summary":"证券之星消息，华特达因11月14日在投资者关系平台上答复投资者关心的问题。近年来人口出生率下降，达因药业遵循循证医学原则，依据专家共识等科学指南，宣传普及并拓展维生素AD等产品的“中大童”市场，同时基于儿童临床需要和健康需求，通过研发和合作等开展医药产品的品类延伸和营养健康产品的品牌延伸，以不断丰富的多元化儿童医药健康产品矩阵，推动公司产品销售和业绩发展。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400014950.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0175","BK0186","BK0122","000915"],"gpt_icon":0},{"id":"2583286765","title":"华特达因：小儿布洛芬栓可用于儿童流感发热","url":"https://stock-news.laohu8.com/highlight/detail?id=2583286765","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583286765?lang=zh_cn&edition=full","pubTime":"2025-11-14 11:37","pubTimestamp":1763091434,"startTime":"0","endTime":"0","summary":"证券之星消息，华特达因(000915)11月14日在投资者关系平台上答复投资者关心的问题。投资者提问：近期儿童流感这么严重公司有这方面的药吗？华特达因回复：您好！目前公司产品小儿布洛芬栓可用于儿童普通感冒和流行性感冒引起的发热。另外公司维生素AD滴剂、益生菌等产品有助于增强儿童免疫力。谢谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400014947.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0122","BK0239","000915","BK0188","BK0186"],"gpt_icon":0},{"id":"2579699274","title":"股市必读：华特达因（000915）10月28日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2579699274","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579699274?lang=zh_cn&edition=full","pubTime":"2025-10-29 04:28","pubTimestamp":1761683294,"startTime":"0","endTime":"0","summary":"截至2025年10月28日收盘，华特达因报收于33.2元，下跌0.54%，换手率1.6%，成交量3.76万手，成交额1.26亿元。董秘最新回复投资者： 尊敬的董秘先生，这是第五次就要咨询贵司同一个问题，望正面回复。当日关注点来自交易信息汇总：10月28日主力资金净流出1365.89万元，散户资金净流入1604.16万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900007574.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0122","000915","BK0175","BK0188","BK0239","BK0186"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1770561302748,"stockEarnings":[{"period":"1week","weight":-0.0068},{"period":"1month","weight":-0.04},{"period":"3month","weight":-0.0802},{"period":"6month","weight":-0.0601},{"period":"1year","weight":0.2566},{"period":"ytd","weight":-0.0275}],"compareEarnings":[{"period":"1week","weight":-0.0127},{"period":"1month","weight":-0.0049},{"period":"3month","weight":0.017},{"period":"6month","weight":0.1184},{"period":"1year","weight":0.243},{"period":"ytd","weight":0.0244}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"山东华特达因健康股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"27598人(较上一季度增加7.66%)","perCapita":"8485股","listingDate":"1999-06-09","address":"山东省临沂市沂南县县城振兴路6号","registeredCapital":"23433万元","survey":"　　山东华特达因健康股份有限公司的主营业务是儿童医药和健康产品的研发、生产和销售业务。公司的主要产品是儿童药品、营养/保健食品、儿童健康用品。","listedPrice":4.68},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华特达因(000915)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华特达因(000915)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华特达因,000915,华特达因股票,华特达因股票老虎,华特达因股票老虎国际,华特达因行情,华特达因股票行情,华特达因股价,华特达因股市,华特达因股票价格,华特达因股票交易,华特达因股票购买,华特达因股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华特达因(000915)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华特达因(000915)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}